In the 12-week, phase 2a DUET study, treatment with TERN-501, a thyroid hormone receptor β agonist, as monotherapy or in combination with TERN-101, a farnesoid X receptor agonist, resulted in dose-dependent reductions in liver fat content as compared to placebo in patients with presumed metabolic dysfunction-associated steatohepatitis.
- Mazen Noureddin
- Naim Alkhouri
- Stephen A. Harrison